Antimicrobial-resistant ESKAPE (E nterococcus faecium, S taphylococcus aureus, K
lebsiella pneumoniae, A cinetobacter baumannii, P seudomonas aeruginosa, and E …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …

Pseudomonas aeruginosa, a Gram-negative bacterium, is recognized for its adaptability and
opportunistic nature. It poses a substantial challenge in clinical settings due to its …

The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in
critically ill patients presents many challenges. Since an effective treatment should be …

The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses
significant challenges in the treatment of healthcare associated infections. An important …

Background Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated
with high mortality. We assessed the efficacy and safety of the combination antibacterial …

Background Ceftolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor
combination that often retains activity against resistant Pseudomonas aeruginosa. The …

P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …